Participating Faculty: Improving Adherence in the Treatment of Type 2 Diabetes Mellitus: Opportunities for Managed Care

Faculty

This supplement to The American Journal of Managed Care discusses patient adherence to prescribed therapies for type 2 diabetes mellitus, including the relationship between adherence, patient outcomes, and treatment costs; potential causes of poor adherence; and strategies to improve adherence.

R. Keith Campbell, RPh, MBA, CDE

Distinguished Professor in Diabetes Care/Pharmacotherapy

Washington State University

College of Pharmacy

Pullman, Washington

David P. Nau, PhD

Senior Director

Quality Strategies

Pharmacy Quality Alliance

Fairfax Station, Virginia

Howard Wild, BS Pharm, RPh

Vice President of Generic Strategies

MedImpact Healthcare Systems

San Diego, California

Faculty Disclosures

These faculty report relationships with the following organizations:

R. Keith Campbell, RPh, MBA, CDE

Lecturer: Eli Lilly, Boehringer Ingelheim

Howard Wild, BS Pharm, RPh

Consultant/Advisory Board/Honoraria: Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, MedImmune, Novo Nordisk, Pfizer, Takeda

David P. Nau, PhD, reports no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.

Funding for the development of this supplement was provided by Novo Nordisk.

Download PDF: Participating Faculty: Improving Adherence in the Treatment of Type 2 Diabetes Mellitus: Opportunities for Managed Care